Impax Laboratories Inc. (IPXL) announced Thursday morning that the FDA has approved RYTARY for the treatment of Parkinson's disease.
Impax Laboratories gapped open sharply higher Thursday and posted gains in early trade, before settling into a range. The stock closed up by 3.61 at $34.60 on above average volume. Impax Laboratories climbed past the upper end of a month and a half long trading range and set a new high for the year.
For comments and feedback: editorial@rttnews.com